Here are 1-2 brief analogies for Synergy CHC (SNYR):

• The Procter & Gamble of health supplements and over-the-counter (OTC) products.
• Like a smaller Kenvue (J&J's spun-off consumer health business) that grows by acquiring established health and wellness brands.

• Over-the-Counter (OTC) Health Products: These are non-prescription medications and health-related items sold directly to consumers for various common ailments or health maintenance.
• Dietary Supplements: These products are designed to supplement the diet and typically contain vitamins, minerals, herbs, amino acids, or other substances for health benefits.

Synergy CHC (SNYR) primarily sells its products directly to individual consumers through various e-commerce channels, including its own brand websites and third-party marketplaces such as Amazon.com. As such, the company does not have "major customer companies" that purchase inventory for resale and account for a significant portion of its revenue in the traditional business-to-business (B2B) sense.

Instead, Synergy CHC serves individual customers, who can be broadly categorized based on their health needs and preferences:

• Individuals seeking cognitive enhancement and brain health support: This category primarily includes consumers who purchase products like Focus Factor, aiming to improve memory, concentration, and overall brain function. This demographic can span various age groups, from students and professionals to older adults concerned with cognitive aging.
• Individuals prioritizing general health, wellness, and specific functional benefits: This broad group encompasses consumers looking for daily nutritional support, immune system boosters, digestive health aids, or specific benefits related to beauty (e.g., hair, skin, nails) and joint health. These customers are served by various supplement lines, including those under the Biova Pharma brand and general wellness gummies.
• Individuals who prefer convenient and palatable supplement delivery methods: With a significant focus on "The Gummy Guys" brand, Synergy CHC caters to consumers who prefer the taste, texture, and ease of consumption of gummy supplements over traditional pills or powders. This category is driven by a preference for an enjoyable and simple daily supplement routine.

Jack Ross, Chief Executive Officer & Chairman

Jack Ross has served as the Chief Executive Officer and Chairman of Synergy CHC since its inception in October 2014. He also previously held the roles of Chief Financial Officer (August 2018 to July 2021, and October 2014 to October 2017) and President (May 2020 to January 2021, and October 2014 to October 2017) at Synergy CHC. Under his leadership, Synergy has acquired eight individual brands since 2015. Mr. Ross is described as a lifetime business builder and entrepreneur with a proven track record across various consumer product verticals. Outside of Synergy CHC, he has served as the Chief Executive Officer of Kenek Brands Inc., an executive consulting firm, since January 2014, and as the Chairman and Chief Executive Officer of Gowan Capital Inc. since May 2011. He is also the President & Chief Executive Officer of SportsClick, Inc. since 2009, and Chief Executive Officer of Boombod Ltd. since 2018.

Jaime Fickett, Chief Financial Officer

Jaime Fickett was appointed as the Chief Financial Officer of Synergy CHC on March 27, 2025, after serving as Interim CFO since December 6, 2024. She has been with Synergy CHC since January 2015, serving as the Senior Vice President of Finance and Operations. Prior to joining Synergy CHC, Ms. Fickett was the Chief Financial Officer of Factor Nutrition Labs, LLC, a dietary supplement company, from August 2006 to January 2015. Her earlier career, from 1999 to 2006, was in the public accounting sector as an auditor.

Alfred Baumeler, President

Alfred Baumeler has served as the President of Synergy CHC since January 2021. Before this role, he was the Executive Vice President of Sales and Marketing for Synergy CHC from August 2015 to December 2020. From September 2012 to August 2015, Mr. Baumeler held the position of Senior Vice President of Marketing for Healthy Natural Systems/Core Science Medica (CSM)/Lifeagen, a nutritional supplement company.

Kelly Dressler, Senior Manager, Regulatory Affairs

Kelly Dressler serves as the Senior Manager of Regulatory Affairs for Synergy CHC.

Larry Pairo, VP of Operations & Supply Chain

Larry Pairo is the Vice President of Operations & Supply Chain at Synergy CHC.

The key risks to Synergy CHC's business include its significant financial challenges and ongoing dilution of shareholder value, a concentrated product portfolio, and exposure to supply chain and regulatory hurdles.

1. Financial Health and Shareholder Dilution: Synergy CHC faces substantial financial risks, highlighted by repeated equity raises that have diluted existing shareholders' stakes. The company has negative shareholder equity and a high debt-to-equity ratio, with operating cash flow that does not adequately cover its debt. In 2024, Synergy CHC reported an accumulated deficit and a working capital deficit, which raises concerns about its ability to continue as a going concern. A shelf registration statement filed in November 2025 further indicates the potential for future capital raises and additional dilution.
2. Concentrated Product Portfolio: Synergy CHC's revenue is heavily dependent on a small number of brands, such as FOCUSfactor and Flat Tummy. This concentration makes the company particularly vulnerable to sudden shifts in consumer preferences or changes in orders from retailers. For example, a rebranding effort for FOCUSfactor in 2024 resulted in a decrease in net revenue and gross profit, demonstrating the impact of reliance on key products.
3. Supply Chain and Regulatory Risks: The company is exposed to risks related to its supply chain and the regulatory environment. Certain ingredients used in Synergy CHC's supplements could be subject to tariffs or new regulatory requirements, potentially increasing costs or leading to product recalls. Furthermore, the company and its suppliers must comply with numerous laws and regulations governing the manufacturing and sale of nutritional supplements, and any changes or non-compliance could lead to increased costs, limitations on product sales, or enforcement actions.

• The emergence and rapid growth of personalized nutrition and AI-driven health recommendation platforms. These services offer highly customized supplement regimens based on individual biometric data, DNA analysis, or detailed health profiles, often delivered via subscription models. This trend directly threatens the traditional, mass-market dietary supplement brands within Synergy CHC's portfolio by shifting consumer preference towards bespoke, data-driven solutions perceived as more effective and tailored.
• The evolving and increasingly challenging landscape of social media and influencer marketing. Many of Synergy CHC's key brands, such as Flat Tummy Co., have historically relied heavily on these channels for customer acquisition and brand visibility. However, rising customer acquisition costs (CAC) due to algorithm changes, stricter platform policies regarding health claims, increasing regulatory scrutiny on influencer disclosures, and growing consumer skepticism towards sponsored content are eroding the effectiveness and cost-efficiency of this critical marketing channel.
• Aggressive expansion of private label brands by major e-commerce platforms, particularly Amazon, into the health, wellness, and dietary supplement categories. These platforms leverage their extensive customer data, logistical dominance, and direct control over their marketplace to offer competitively priced products with prominent placement, directly competing with Synergy CHC's brands, especially those with a strong e-commerce focus. This threatens to erode market share and pricing power for SNYR's portfolio.

Synergy CHC Corp. (SNYR) operates within the broader consumer health, beauty, and lifestyle product markets, with its main offerings falling into categories such as dietary supplements, general health and wellness products, and over-the-counter (OTC) medications. The addressable markets for these product categories are substantial both globally and within the United States.

• Global Health and Wellness Market: The global health and wellness market was estimated at USD 6.87 trillion in 2025 and is projected to reach USD 11 trillion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 5.40% from 2025 to 2034. Other reports estimate the global wellness market reached USD 6.3 trillion by the end of 2023 and is forecast to hit USD 9 trillion by 2028, growing at a CAGR of 7.3% from 2023 to 2028. North America held the largest share of the global market in 2024.

• U.S. Health and Wellness Market: The U.S. health and wellness market size was estimated at USD 2.31 trillion in 2025 and is expected to expand to approximately USD 3.70 trillion by 2034, with a CAGR of 5.40% from 2025 to 2034. Another projection indicates the U.S. health and wellness market was valued at USD 939 billion in 2024 and is expected to reach USD 1,560 billion by 2033, exhibiting a CAGR of 5.8% from 2025 to 2033.

• Global Dietary Supplements Market: The global dietary supplements market size was estimated at USD 192.65 billion in 2024 and is projected to reach USD 414.52 billion by 2033, growing at a CAGR of 8.9% from 2025 to 2033. North America dominated this market in 2024 with a 36.5% share.

• U.S. Dietary Supplements Market: The U.S. dietary supplements market size was estimated at USD 63.92 billion in 2024 and is projected to reach USD 124.22 billion by 2033, growing at a CAGR of 7.7% from 2025 to 2033. Other figures suggest the U.S. market size was USD 71.60 billion in 2024 and is expected to reach around USD 162.40 billion by 2033, with a CAGR of 9.47%.

• Global Over-the-Counter (OTC) Consumer Health/Drugs Market: The global OTC Consumer Health Products Market size is projected to be USD 223.51 billion in 2025, with sales expected to reach USD 413.71 billion by 2033, at a CAGR of 8.00% from 2025 to 2033. North America accounted for a significant portion of this market, with an estimated market size of USD 82.70 billion in 2025 and a projected CAGR of 5.8% from 2025 to 2033.

• U.S. Over-the-Counter (OTC) Drugs Market: The U.S. over-the-counter (OTC) drugs market was valued at USD 41.93 billion in 2024 and is expected to reach USD 69.65 billion by 2033, growing at a CAGR of 5.8% during the forecast period 2025–2033. Another report estimates the U.S. OTC drugs market size at USD 24.81 billion in 2025, projected to increase to approximately USD 44.17 billion by 2034, expanding at a CAGR of 6.60% from 2025 to 2034.

Synergy CHC (SNYR) is anticipated to drive future revenue growth over the next two to three years through several key strategies:

1. International Expansion of FOCUSfactor: The company expects to accelerate growth for its flagship brain health supplement, FOCUSfactor, by penetrating new international markets. This expansion is highlighted by recent retail wins across various channels and entry into three new markets, projected to contribute to meaningful gains in late 2025.
2. Domestic Retail Channel Expansion for FOCUSfactor: Domestically, Synergy CHC aims to expand FOCUSfactor's presence through new retail wins across mass, grocery, pharmacy, convenience, and wholesale channels. These efforts are expected to drive significant revenue growth in late 2025.
3. Launch of New Products and Line Extensions: Synergy CHC plans to introduce new products and extend existing lines, including the FOCUSfactor functional beverage line and the development of GLP-1 support products. These new offerings are strategic initiatives positioned for future growth.
4. Strategic Acquisitions: The company's business model is centered on acquiring and growing a portfolio of best-in-class brands within the health, wellness, and beauty sectors. This strategy of identifying and integrating proven brands is a consistent driver for future revenue.

Share Issuance

• Synergy CHC Corp completed an Initial Public Offering (IPO) in October 2024, issuing 1,150,000 shares of common stock at $9.00 per share, which generated approximately $8.4 million in net proceeds. These funds were used to repay related party promissory notes and for general corporate purposes.
• In August 2025, Synergy CHC Corp priced an underwritten public offering of 1,750,000 shares of common stock at $2.50 per share, aiming to raise $4.375 million in gross proceeds for working capital and general corporate purposes.
• Shareholders approved in June 2025 an amendment to increase the 2024 Equity Incentive Plan to 2,252,102 shares and authorized the issuance of up to 1,000,000 shares of preferred stock.

Inbound Investments

• Synergy CHC Corp secured a $20 million financing agreement with ACP Agency, LLC in June 2025. This facility included an initial $15 million term loan, a $2.5 million delayed draw option, and a $2.5 million uncommitted term loan expansion, intended for debt reduction, liquidity enhancement, and global growth.
• Institutional investors have purchased approximately $1.39 million worth of Synergy CHC stock over the last 24 months, reflecting ongoing investment in the company.

Capital Expenditures

• Over the last 12 months leading up to November 2025, Synergy CHC's capital expenditures were reported as -$5.00, indicating minimal capital investment during this period.